Advertisement
Organisation › Details
Reference Capital S.A.
As the oldest firm dedicated to private investments in Switzerland, Reference Capital SA (formerly Genevest SA) has backed outstanding companies in tech, biotech and medtech since 1983. Reference Capital’s team and network of experts span 3 continents. They provide access, expertise, and protection of interests to a select number of family offices and long-term investors seeking superior returns and investments with purpose. Reference Capital’s new investment programme, launched in 2019, connects investors to a curated and tailor-made portfolio of Private Equity and Venture Capital Funds as well as direct investments, shaping the future of the life sciences and technology sectors. Reference Capital’s direct-early stage investments with successful exits include Swiss life sciences companies, such as Actelion, Axovan, Endoart, Kuros, Neocutis, Novimmune and Thommen Medical. *
Start | 2019-09-26 renamed before | |
Predecessor | Genevest S.A. | |
Industry | private equity | |
Industry 2 | LIFE SCIENCES | |
Region | Switzerland_oo | |
Country | Switzerland | |
City | n. a. | |
Address record changed: 2019-10-01 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: T3 Pharmaceuticals AG. (9/26/19). "Press Release: Closing of Financing Round and Strengthening of Development Team Paves the Way for T3 Pharma to Enter the Clinic". | ||
Record changed: 2020-10-11 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top